Where all your ID needs are met! Sort of.
I reckon it’s time to write about new antibiotics. I do not like beta-lactamases. Mostly due to their ability to confuse clinicians, however also because it makes it difficult to pick an antibiotic for certain infections. I have written extensively about these, so look at this post. In general, carabepenemases and cephalosporinases within class A
Extended spectrum-beta lactamase producing organisms are those gram negatives that make beta-lactamases that inhibit third and fourth generation cephalosporins. As such, things such as piperacillin-tazobactam tends to show up as susceptible in antibiograms, however there has been a push lately towards the use of carbapenems as therapy for infections with these organisms. It seems kind
I think we can all agree that resistance is inevitable, despite what the quote says, in the world of infectious diseases. More and more, the use of broad spectrum antibiotics (looking at you, vanco-zosyn!) brings upon more resistant organisms, with beta-lactamases being one of the key methods of resistance in many gram negative bacteria. As
Gram negatives are a nightmare. Or at least, they are becoming a nightmare with all new patterns of resistance, beta-lactamases and carbapenamases, and plasmid-encoded resistances bringing forth the new generation of beta-lactam and beta-lactamase combinations that I find difficult to keep up with. The definitions of multi-drug resistant organisms tend to be more geared towards
Beta-Lactamases make my head hurt. They are so many of them and they impact the therapeutic options for a lot of the infections that we treat. Due to this resistance mechanism, there has been an influx of new beta-lactam/beta-lactamase combinations (ceftazidime-avibactam, meropenem-vaborbactam, etc) to overcome this phenomena. So first, this is a beta-lactam: The penicillin-binding
Dr. Germophile 